Risk factors

The ODYSSEY Trial Ends Well— But Will It Be Enough?

Sanofi and Regeneron achieved a modest victory with the much anticipated ODYSSEY Outcomes trial of its cholesterol lowering drug Praluent (alirocumab). The trial met its primary endpoint and even reported a significant improvement in all-cause mortality. But the mortality finding has an asterisk attached to it and it is far from clear whether the overall ...

Already a member?

Login to keep reading.

© 2021 the limbic